Trevi Therapeutics Inc. Common Stock (TRVI)
Stock · NASDAQ · Health Care
$16.79as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$14.05
Industry
Biotechnology: Pharmaceutical Preparations
About TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 34
- Website
- www.trevitherapeutics.com/
Fundamentals
- 1-day range
- $16.63$18.09
- Market cap
- $2.54B
- P/E (trailing)
- —
- P/E (forward)
- -29.10
- EPS (trailing)
- $-0.34
- Dividend yield
- —
- Beta
- 0.91
- Avg. volume
- 2.13M
52-week range
$6.93$20.22
Next earnings: November 12, 2026 · EPS estimate $-0.13confirmed
Forecasts
11 analyst ratings
Buy 94%
Hold 6%
Sell 0%
1-year price forecast
High
$40
+138.2%
Median
$25
+48.9%
Low
$23
+37.0%
Trevi Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TRVITrevi Therapeutics Inc. Common Stock$16.78▼ 6.60%Market cap $2.54BP/E —$6.93$20.22
- IMNMImmunome Inc. Common Stock$27.57▼ 4.50%Market cap $2.61BP/E —$8.67$30.06
- RAREUltragenyx Pharmaceutical Inc. Common Stock$25.62▼ 2.46%Market cap $2.46BP/E —$18.29$39.89
- SUPNSupernus Pharmaceuticals Inc. Common Stock$43.76▼ 0.97%Market cap $2.67BP/E —$42.45$59.68
- NKTRNektar Therapeutics Common Stock$72.57▼ 2.66%Market cap $2.38BP/E —$27.87$109
- PGENPrecigen Inc. Common Stock$6.94▼ 3.55%Market cap $2.36BP/E —$2.99$7.72
- VERAVera Therapeutics Inc. Class A Common Stock$34.19▼ 1.18%Market cap $2.31BP/E —$21.2$56.05
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TRVI Trevi Therapeutics Inc. Common Stock | $2.54B | — | $16.78 | ▼ 6.60% | $6.93$20.22 |
| IMNM Immunome Inc. Common Stock | $2.61B | — | $27.57 | ▼ 4.50% | $8.67$30.06 |
| RARE Ultragenyx Pharmaceutical Inc. Common Stock | $2.46B | — | $25.62 | ▼ 2.46% | $18.29$39.89 |
| SUPN Supernus Pharmaceuticals Inc. Common Stock | $2.67B | — | $43.76 | ▼ 0.97% | $42.45$59.68 |
| NKTR Nektar Therapeutics Common Stock | $2.38B | — | $72.57 | ▼ 2.66% | $27.87$109 |
| PGEN Precigen Inc. Common Stock | $2.36B | — | $6.94 | ▼ 3.55% | $2.99$7.72 |
| VERA Vera Therapeutics Inc. Class A Common Stock | $2.31B | — | $34.19 | ▼ 1.18% | $21.2$56.05 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough PlatformSeekingAlpha · 8/20/2026
- Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28Benzinga · 8/14/2026
- Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25Benzinga · 8/7/2026
- Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30Benzinga · 8/7/2026
- Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call TranscriptSeekingAlpha · 8/6/2026
- Trevi Therapeutics Q2 EPS $(0.11), InlineBenzinga · 8/6/2026
Insider Activity
Insider Actions →Acquired
175.0K
Disposed
0
- Heffernan Michael Thomas · June 3, 2026 · Grant35.0K
- David P. Meeker · June 3, 2026 · Grant35.0K
- Edward T. Mathers · June 3, 2026 · Grant35.0K
- Colangelo Dominick · June 3, 2026 · Grant35.0K
- VANLENT ANNE · June 3, 2026 · Grant35.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 134.18M
- Total value held
- $1.60B
- Institutional holders
- 194
Top holders this quarter
- Unknown13.22M
- Unknown10.24M
- Unknown9.94M
- Unknown8.04M
- Unknown5.19M
- Unknown5.09M
- Unknown4.98M
- Unknown3.97M
- Unknown3.71M
- Unknown3.30M
See the full, filterable feed with live charts on the MarketWall dashboard.